Lumipulse® G SARS-CoV-2 S-IgG
Lumipulse G SARS-CoV-2 S-IgG is an assay system, including a set of immunoassay reagents, for the quantitative measurement of IgG-type antibodies SARS-CoV-2 spike protein (SARS-CoV-2 S-IgG) in specimens based on CLEIA technology by a specific two-step immunoassay method on the LUMIPULSE G System and with results that are available in up to 30 minutes.
Product number 232231
Click here to navigate
- Conditions of sale
- Related products
- Product inquiry
CLEIA - Chemiluminescent Enzyme Immunoassay
Test principle: Two-Step sandwich assay
See the LUMIPULSE G1200 working in this video:
Conditions of sale
To read the end user conditions of sale for this product please visit our Resource center.
Lumipulse G SARS-CoV-2 Ag was the first high-sensitive nucleocapsid protein antigen assay launched on a fully automated chemiluminescent platform.
May 27, 2021
Since November 2020 Fujirebio Europe and CENTOGENE have partnered to leverage LUMIPULSE® G technology for large-scale COVID-19 antigen testing in...
May 11, 2021
During this webinar Dr. Francesco Bonella (MD - Center for Interstitial & Rare Lung Disease, Department of Pulmonology, Ruhrlandklinik University...
Oct 19, 2020
How does the coronavirus disease Covid-19 impact Fujirebio's operations?
Please see the following statement on the impact of coronavirus disease Covid-19 on the operations of Fujirebio Europe (updated January 19, 2021).
Lumipulse® G SARS-CoV-2 S-IgG Controls
Product number 232552 -
For in vitro diagnostic (IVD) use as quality controls, to monitor the precision and accuracy of the Lumipulse G SARS-CoV-2 S-IgG assay on the automated LUMIPULSE G System. The assay using this control is performed to quantitatively measure IgG antibodies to SARS-CoV-2 Spike (S) Receptor Binding Domain (RBD) in human serum or plasma and is intended to be used in the assessment of the immune response to the SARS-CoV-2 S protein.CE marked
Lumipulse® G SARS-CoV-2 Ag
Product number 260340, 231869 -
For in vitro diagnostic (IVD) use with the Lumipulse G system for detection and quantitative measurement of SARS-CoV-2 nucleocapsid protein antigen in human nasopharyngeal swab or saliva. As a diagnostic tool for the confirmation of a SARS-CoV-2 infection.CE marked
Lumipulse® G KL-6 (Krebs von den Lungen)
Product number 233207 -
Immunoreaction cartridges for in vitro diagnostic (IVD) use with the LUMIPULSE G System for the quantitative measurement of sialylated carbohydrate antigen, KL-6 in serum or plasma.CE marked
Product number 703380 -
The LUMIPULSE G600II is the latest member of the Lumipulse G series of chemiluminescent enzyme immunoassay analyzers (CLEIA) from Fujirebio.CE marked
Product number 232002 -
A robust, mid-sized and fully automated chemiluminescent enzyme immunoassay (CLEIA) system from the already widely successful LUMIPULSE series.CE marked
iAMP COVID-19 SANO Assay
Product number 81104, 80762, 80812 -
Qualitative detection of nucleic acid from the SARS-CoV-2 in nasopharyngeal swabs, oropharyngeal swabs and saliva specimens from individuals with signs and symptoms of infection who are suspected of COVID-19.CE marked